Below is a snapshot of the Web page as it appeared on 9/15/2021 (the last time our crawler visited it). This is the version of the page that was used for ranking your search results. The page may have changed since we last cached it. To see what might have changed (without the highlights), go to the current page.
You searched for: +trelegyelliptainhalercoupons We have highlighted matching words that appear in the page below.
Bing is not responsible for the content of this page.
TrelegyEllipta (fluticasone/umeclidinium/vilanterol) is used to treat chronic obstructive pulmonary disease (COPD). This life-changing medication was approved by the FDA in 2017 as a longterm, once-daily inhaler to combat the issues associated with COPD, like airflow obstruction.
In this guide, we’ll discuss what TrelegyEllipta can do for you, how it works, common side effects, and also give you information on how to save money on this medication.
*Savings calculated based on pharmacy typical, publicly available, stock rate pricing. We cannot guarantee, certify correct, or confirm any medical information or pricing data. All information is provided for convenience from automated sources that have not been reviewed for accuracy.
Trelegyellipta Discount Coupon - Save Up To 75%* Off!
The free Pharmacy CouponsTrelegyellipta Coupon and Discount Card can save you up to 75%* off your prescription prices. All you have to do is print the coupon and bring it to the pharmacy to receive the benefits of our drug discount program. This coupon is not insurance and is not valid in combination with any government-sponsored drug plans.
Average Savings: 75%* Off
How to use your Trelegyellipta Coupon:
Simply click the "Get Trelegyellipta Coupon" button and choose how you want to receive your Trelegyellipta coupon. You can get it by Print, Email, or even a Text Message.
After getting your coupon, just show it to your pharmacist when you fill your prescription.
From there, enjoy up to 75%* off your prescription!
Drug Name:Trelegyellipta Generic name: Fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
The active ingredients of Trelegyellipta are:
fluticasone furoate; umeclidinium bromide; vilanterol trifenatate Drug Class: Corticosteroid [EPC]
Corticosteroid Hormone Receptor Agonists [MoA] ,
Cholinergic Antagonists [MoA] ,
Adrenergic beta2-Agonists [MoA] ,
beta2-Adrenergic Agonist [EPC]
TrelegyEllipta: What It Does and How It works?
TrelegyEllipta is a combination drug that uses fluticasone furoate (an inhaled corticosteroid), umeclidinium (an anticholinergic), and vilanterol (a long-acting beta2-adrenergic agonist). Using this combination of medicine helps combat the airflow obstruction found in patients affected by COPD, chronic bronchitis, and emphysema.
It is not to be used for people suffering from asthma or other acute bronchospasm-related illnesses.
If you’ve been diagnosed with COPD, chronic bronchitis, emphysema, or any other inflammatory lung disease, TrelegyEllipta may be able to help. Those who smoke or have smoked in the past may develop COPD or any breathing ailments similar to COPD should consider the benefits of TrelegyEllipta.
The combination of the three active substances in TrelegyEllipta helps combat the symptoms of COPD. The European Medicines Agency lists out the way each part of the drug works.
Fluticasone furoate works as an immune-suppressing corticosteroid. It works by attaching to different receptors on your immune cells. This keeps your system from causing inflammation, which leads to less impacted airways.
Umeclidinium bromide causes the airways to relax by blocking certain receptors. These receptors usually cause the contraction of muscles, so this chemical allows for your airways to remain unconstricted.
Vilanterol is described as a long-acting beta-2 agonist. It works by attaching to beta-2 receptors of certain muscle cells in your body. By activating these beta-2 receptors, it relaxes these muscles, allowing for an open airway.
By combining these three key ingredients, TrelegyEllipta alleviates the major symptoms of COPD. Patients using this medication can reduce their exacerbations, or flare-ups, and improve their ability to breath.
TrelegyEllipta Dosage and Usage Information
TrelegyEllipta is a once-daily inhaler. It combines 100 mcg of fluticasone furoate, 62.5 mcg of umeclidinium, and 25 mcg of vilanterol. Each inhaler contains a counter to track the days of treatment you have left and contains 30 days of treatment. Simple steps to take the daily medication is also provided:
Step one: Slide the cover down to expose the mouthpiece. This will cause the device to “click,” which will reduce the counter by one. You do not need to shake your inhaler. After you slide the cover, it is ready to use.
Step two: Breathe out while holding the inhaler away from your mouth. Do not breathe out into the mouthpiece.
Step three: Inhale the medication. Put the mouthpiece to your lips and close them firmly around it. Then, inhale in one deep breath. Do not block the air vent with your fingers. Do not breathe through your nose. After your steady inhale, hold your breath for three to four seconds.
Step four: Breathe out slowly and gently. You may not taste or feel the medication, but do NOT take another dose.
Step five: Close the inhaler. If needed, you can clean the mouthpiece with a clean tissue, but routine cleaning is not required.
Step six: Rinse your mouth. Without swallowing the water, rinse your mouth out and spit after you have used your inhaler.
TrelegyEllipta’s Potential Side Effects and Safety Concerns
The active ingredients in this inhaler can cause serious asthma-related events. The FDA warns against using it for any acute symptoms. It is also recommended that you do not combine this medication with any other long-acting beta2-adrenergic agonist (LABA) because it could result in an overdose.
TrelegyEllipta may result in infections of the mouth and pharynx, which rinsing after a dose can help prevent. The inhaler may also increase the risk of pneumonia for people suffering from COPD. Further, the medicine may worsen infections like a fungal infection, existing tuberculosis, as well as viral, bacterial, and parasitic infections.
The common side effects include:
TrelegyEllipta does carry some other warnings and concerns from the FDA including the following:
The risk of serious asthma-related events increases when using LABA monotherapy.
Do not initiate in acutely deteriorating COPD. Do not use to treat acute symptoms.
Do not use in combination with additional medicine containing a LABA because of the risk of overdose.
A more serious or even fatal course of chickenpox or measles can occur in susceptible patients.
There is a risk of impaired adrenal function when transferring from systemic corticosteroids.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals.
Paradoxical bronchospasm may occur.
Beta-adrenergic stimulation may affect patients with cardiovascular disease.
May cause a decrease in bone mineral density.
Glaucoma and cataracts may occur with long-term use of ICS.
Worsening of urinary retention may occur.
Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.
May cause hypokalemia and hyperglycemia.
Possible Drug Interactions With TrelegyEllipta
TrelegyEllipta has shown to sometimes interact poorly when combining it with other medications. Be aware of these possibilities and use caution when combining with:
Inhibitors of Cytochrome P450 3A4 like:
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants
Beta-adrenergic Receptor Blocking Agents may cause severe bronchospasm in patients with COPD
DON'T MISS OUT ON SAVINGS Sign up to our mailing list to hear about the latest deals and savings
Invalid email address
Retrieve your coupon now
Select preferred method below to receive
your coupon instantly